| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 02/25/2021 |
3. Issuer Name and Ticker or Trading Symbol
IBERE PHARMACEUTICALS [ IBER ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Class B Ordinary Shares(1) | (1) | (1) | Class A Ordinary Shares | 3,350,000(2)(3) | (1) | D | |
| Explanation of Responses: |
| 1. As described in the issuer's registration statement on Form S-1 (File No. 333-252863) (the "Registration Statement") under the heading "Description of Securities--Founder Shares," the shares of Class B ordinary shares, par value $0.0001 per share, will automatically be converted into shares of Class A ordinary shares, par value $0.0001 per share, at the time of the issuer's initial business combination, on a one-for-one basis subject to adjustment pursuant to certain anti-dilution rights described therein. |
| 2. These shares represent Class B ordinary shares held by PIPV Capital LLC (the "Sponsor") acquired pursuant to a subscription agreement by and between the Sponsor and the issuer and a subsequent share dividend of Class B ordinary shares to the Sponsor. The Class B ordinary shares owned by the Sponsor includes up to 450,000 shares that are subject to forfeiture in the event the underwriters of the issuer's initial public offering do not exercise in full their over-allotment option as described in the issuer's Registration Statement. |
| 3. These shares are held of record by the Sponsor. The Sponsor is beneficially owned and controlled by Lisa Gray, Osagie Imasogie, and Zoltan Kerekes, each of whom may be deemed to have beneficial ownership over these shares. Each such person disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest they may have therein, directly or indirectly. |
| /s/ Osagie Imasogie Chief Executive Officer, on behalf of PIPV Capital LLC | 02/25/2021 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||